1YRSBIO-RAY BIOTECH. CO., LTD. PABP BRANCH

FIRMENÜBERSICHT

Firmenalbum3

Grundlegende Informationen
With over 35 years of experience in medical research and clinical work, our expertise lies in immunology and oncology. We adhere to the belief of seeking non-harmful remedies and strive to develop natural, safe, and effective healthcare methods. Our outstanding research achievements include inventing DNA vaccines for treating allergic diseases as early as 1996, publishing in the prestigious scientific journal "Nature Medicine," and establishing our reputation as an internationally renowned immunology expert. Throughout years of clinical work, we observed that current treatments for immune-related diseases mostly focus on symptom control without addressing the underlying immune system disorder. These treatments are like "band-aid solutions" that merely provide temporary relief. After dedicated research efforts, we successfully developed the first indigenous anti-allergic probiotic strain in Taiwan. Through rigorous scientific evidence from cell experiments, animal studies, and human trials, our product obtained international patents and certifications as a nationally recognized health food that assists in allergy management. Its success in the market ignited the probiotics trend in Taiwan, and even after more than a decade, its popularity remains strong, propelling the functional probiotics industry in Taiwan forward.
  • Transaktionen
    -
  • Reaktionszeit
    ≤6h
  • Reaktionsrate
    90.91%
Unternehmenstyp
Hersteller
Land/Region
Taiwan, China
HauptprodukteGesamtzahl der Beschäftigten
51 - 100 People
Gesamtjahresumsatz
Below US$1 Million
Gründungsjahr
2012
Zertifizierungen(3)Produkt-Zertifizierungen
-
Patente
-
Marken
-
Hauptmärkte

PRODUKTKAPAZITÄT

Fabrikinformationen

Fabrikgröße
3,000-5,000 square meters
Land/Region der Fabrik
No. 21-3, Shennong E. Rd., Changzhi Township, Pingtung County 90846, Taiwan (R.O.C.)
Anzahl der Produktionslinien
3
Auftragsproduktion
OEM Service Offered
Jährlicher Produktionswert
Above US$100 Million